We spoke to Professor Jean-François Obadia (Civils Hospices of Lyon, Lyon, France) about the 2-year follow up from the MITRA-FR trial, and how he would interpret the differing results from recent studies into the efficacy of the MitraClip in patients with mitral regurgitation. Finally, he touches on which patients might be likely to benefit from the intervention and how physicians can best identify them.
Speaker’s Disclosures: Jean-François Obadia has received research grants from Abbott and the French Ministry of Health and is a consultant for Dealcroix-Chevalier, Lanadanger, Medtronic, SJM (Abbott), Novartis and Sorin.
1. What update can you provide from the 2-year follow up of the MITRA-FR trial? (0:05)
2. How would you interpret the differing results between recent studies into the efficacy of MitraClip in patients with mitral regurgitation? (1:00)
3. How can physicians identify patients most likely to benefit from this intervention? (1:44)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Society of Cardiology (ESC) Congress 2019 in Paris, France, September 2019.
Share this Video
Related Videos In Hypertension
Clara Chow, ESC 2021 – the QUARTET Study
Dr Clara Chow (Professor of Medicine, Academic Director Westmead Applied Research Centre, University of Sydney, Sydney, Australia) kindly shared her thoughts on the limitations of current treatment paradigms for hypertension, the quad pill for hypertension, and the QUARTET study, from the virtual ESC Congress 2021. Questions What are the limitations of current treatment paradigms for […]
Kazem Rahimi, ESC 2021 – the Blood Pressure Lowering Treatment Trialists Collaboration
Dr Kazem Rahimi (Professor of Cardiovascular Medicine and Population Health, University of Oxford, Oxford, UK) kindly shared his thoughts on the Blood Pressure Lowering Treatment Trialists Collaboration (BPLTTC), its aims, and the benefits of antihypertensive medicines in older people from the virtual ESC Congress 2021. Questions Could you tell us a little about the Blood […]
Kazuomi Kario, ESC 2021 – the HERB Digital Therapeutics System and the HERB-DH1 Study
Prof. Kazuomi Kario (Professor, Jichi Medical University, Shimotsuke, Tochigi, Japan) kindly shared his thoughts on the HERB digital therapeutics system for essential hypertension and the HERB-DH1 study from the virtual ESC Congress 2021. Questions Could you give us a brief overview of the HERB digital therapeutics system for essential hypertension? (0.14) What were the aims, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!